<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Pain Med</journal-id><journal-id journal-id-type="iso-abbrev">Pain Med</journal-id><journal-id journal-id-type="pmc-domain-id">2894</journal-id><journal-id journal-id-type="pmc-domain">painmed</journal-id><journal-id journal-id-type="publisher-id">painmedicine</journal-id><journal-title-group><journal-title>Pain Medicine: The Official Journal of the American Academy of Pain Medicine</journal-title></journal-title-group><issn pub-type="ppub">1526-2375</issn><issn pub-type="epub">1526-4637</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10906713</article-id><article-id pub-id-type="pmcid-ver">PMC10906713.1</article-id><article-id pub-id-type="pmcaid">10906713</article-id><article-id pub-id-type="pmcaiid">10906713</article-id><article-id pub-id-type="pmid">38243702</article-id><article-id pub-id-type="doi">10.1093/pm/pnad169</article-id><article-id pub-id-type="publisher-id">pnad169</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Co-Morbid Pain &amp; Substance Use Disorders Section</subject><subj-group subj-group-type="category-toc-heading"><subject>Original Research Article</subject></subj-group></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00010</subject></subj-group></article-categories><title-group><article-title>Opioid therapy trajectories of patients with chronic non-cancer pain over 1 year of follow-up after initiation of short-acting opioid formulations</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0484-3705</contrib-id><name name-style="western"><surname>Acharya</surname><given-names initials="M">Mahip</given-names></name><degrees>BS</degrees><aff>
<institution>Division of Pharmaceutical Evaluation and Policy, Department of Pharmacy Practice, University of Arkansas for Medical Sciences</institution>, Little Rock, AR 72205, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7776-6157</contrib-id><name name-style="western"><surname>Hayes</surname><given-names initials="CJ">Corey J</given-names></name><degrees>PharmD, PhD</degrees><aff>
<institution>Department of Biomedical Informatics, College of Medicine, University of Arkansas for Medical Sciences</institution>, Little Rock, AR 72205, <country country="US">United States</country></aff><aff>
<institution>Center for Mental Healthcare and Outcomes Research, Central Arkansas Veterans Healthcare Systems</institution>, North Little Rock, AR 72211, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="C">Chenghui</given-names></name><degrees>PhD</degrees><aff>
<institution>Division of Pharmaceutical Evaluation and Policy, Department of Pharmacy Practice, University of Arkansas for Medical Sciences</institution>, Little Rock, AR 72205, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Painter</surname><given-names initials="JT">Jacob T</given-names></name><degrees>PharmD, PhD</degrees><aff>
<institution>Division of Pharmaceutical Evaluation and Policy, Department of Pharmacy Practice, University of Arkansas for Medical Sciences</institution>, Little Rock, AR 72205, <country country="US">United States</country></aff><aff>
<institution>Center for Mental Healthcare and Outcomes Research, Central Arkansas Veterans Healthcare Systems</institution>, North Little Rock, AR 72211, <country country="US">United States</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dayer</surname><given-names initials="L">Lindsey</given-names></name><degrees>PharmD</degrees><aff>
<institution>College of Pharmacy, University of Arkansas for Medical Sciences</institution>, Little Rock, AR 72205, <country country="US">United States</country></aff></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Martin</surname><given-names initials="BC">Bradley C</given-names></name><degrees>PharmD, PhD</degrees><xref rid="pnad169-cor1" ref-type="corresp"/><aff>
<institution>Division of Pharmaceutical Evaluation and Policy, Department of Pharmacy Practice, University of Arkansas for Medical Sciences</institution>, Little Rock, AR 72205, <country country="US">United States</country></aff></contrib></contrib-group><author-notes><corresp id="pnad169-cor1"><italic toggle="yes">Corresponding author:</italic> Division of Pharmaceutical Evaluation and Policy, Department of Pharmacy Practice, University of Arkansas for Medical Sciences, Rahn Building, Room 6259, 4301 W. Markham Street, Slot 522, Little Rock, AR 72205, USA. Email: <email>Bmartin@uams.edu</email></corresp></author-notes><pub-date pub-type="collection"><month>3</month><year>2024</year></pub-date><pub-date pub-type="epub" iso-8601-date="2024-01-18"><day>18</day><month>1</month><year>2024</year></pub-date><volume>25</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">456943</issue-id><fpage>173</fpage><lpage>186</lpage><history><date date-type="accepted"><day>09</day><month>11</month><year>2023</year></date><date date-type="received"><day>31</day><month>10</month><year>2023</year></date><date date-type="corrected-typeset"><day>25</day><month>1</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>01</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>18</day><month>01</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-01-19 21:25:32.677"><day>19</day><month>01</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024. Published by Oxford University Press on behalf of the American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref>https://academic.oup.com/pages/standard-publication-reuse-rights</ali:license_ref><license-p>This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://academic.oup.com/pages/standard-publication-reuse-rights">https://academic.oup.com/pages/standard-publication-reuse-rights</ext-link>)</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pnad169.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pnad169.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Objective</title><p>This study compared opioid utilization trajectories of persons initiating tramadol, short-acting hydrocodone, or short-acting oxycodone, and it characterized opioid dose trajectories and type of opioid in persistent opioid therapy subsamples.</p></sec><sec id="s2"><title>Methods</title><p>A retrospective cohort study of adults with chronic non-cancer pain who were initiating opioid therapy was conducted with the IQVIA PharMetrics<sup>&#174;</sup> Plus for Academics data (2008&#8211;2018). Continuous enrollment was required for 6&#8201;months before (&#8220;baseline&#8221;) and 12&#8201;months after (&#8220;follow-up&#8221;) the first opioid prescription (&#8220;index date&#8221;). Opioid therapy measures were assessed every 7&#8201;days over follow-up. Group-based trajectory modeling (GBTM) was used to identify trajectories for any opioid and total morphine milligram equivalent measures, and longitudinal latent class analysis was used for opioid therapy type.</p></sec><sec id="s3"><title>Results</title><p>A total of 40&#160;276 tramadol, 141&#160;023 hydrocodone, and 45&#160;221 oxycodone initiators were included. GBTM on any opioid therapy identified 3 latent trajectories: early discontinuers (tramadol 39.0%, hydrocodone 54.1%, oxycodone 61.4%), late discontinuers (tramadol 37.9%, hydrocodone 39.4%, oxycodone 33.3%), and persistent therapy (tramadol 6.7%, hydrocodone 6.5%, oxycodone 5.3%). An additional fourth trajectory, intermittent therapy (tramadol 16.4%), was identified for tramadol initiators. Of those on persistent therapy, 2687 individuals were on persistent therapy with tramadol, 9169 with hydrocodone, and 2377 with oxycodone. GBTM on opioid dose resulted in 6 similar trajectory groups in each persistent therapy group. Longitudinal latent class analysis on opioid therapy type identified 6 latent classes for tramadol and oxycodone and 7 classes for hydrocodone.</p></sec><sec id="s4"><title>Conclusion</title><p>Opioid therapy patterns meaningfully differed by the initial opioid prescribed, notably the presence of intermittent therapy among tramadol initiators and higher morphine milligram equivalents and prescribing of long-acting opioids among oxycodone initiators.</p></sec></abstract><kwd-group><kwd>tramadol</kwd><kwd>hydrocodone</kwd><kwd>oxycodone</kwd><kwd>trajectory analysis</kwd><kwd>latent class</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>UAMS</institution><institution-id institution-id-type="DOI">10.13039/100008519</institution-id></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Translational Research Institute</institution><institution-id institution-id-type="DOI">10.13039/501100020492</institution-id></institution-wrap></funding-source></award-group><award-group award-type="grant"><funding-source><institution-wrap><institution>NIH</institution><institution-id institution-id-type="DOI">10.13039/100000002</institution-id></institution-wrap></funding-source><award-id>UL1TR000039</award-id></award-group></funding-group><counts><page-count count="14"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>